Antiva Biosciences closes $ 31 million Series D equity financing

0

SOUTH SAN FRANCISCO, CALIFORNIA., November 2, 2021 / PRNewswire / – Antiva Biosciences, a biopharmaceutical company developing novel topical therapeutics to treat pre-cancerous cancer caused by human papillomavirus (HPV) infection, today announced the close of a $ 31 million Series D equity financing. The financing was backed by a consortium of leading life science investors led by Adjuvant Capital, a leading global venture company in the women’s health space, and GV, formerly Google Ventures. The new investors HBM Healthcare Investments, Avestria Ventures, Gaingels and Mana Ventures as well as existing investors such as Canaan Partners, Sofinnova Ventures, Lumira Ventures, Brace Pharma Capital, Sirona Capital, Osage University Partners, Dong-A ST and Alexandria were also involved in the financing Venture investments. In connection with the financing, Jenny Yip, Managing Partner, Adjuvant Capital, will join Antiva’s board of directors.

The proceeds from the funding will support the advancement of the company’s lead development candidate, ABI-2280, including the near-term advancement of the compound in Phase 1 and 2a clinical trials as a potential treatment for high-grade cervical intraepithelial neoplasia (HSIL, CIN 2,3) . ABI-2280 is a prodrug of an acyclic nucleoside phosphonate known to be potent antiviral activity that directly blocks HPV replication and induces apoptosis in HPV infected lesions while sparing normal cells. Antiva has used its engineering expertise to create a topical formulation of the active ingredient that is rapidly absorbed into epithelial cells and avoids the potential systemic toxicity often associated with the systemic administration of potent antiviral drugs. The company plans to initiate a Phase 1 clinical trial of ABI-2280 in the fourth quarter, with data expected in the first half of 2022.

“This round of funding comes at an active and exciting time for Antiva as we are rapidly approaching the start of our first Phase 1 clinical trial of ABI-2280. Given the industry interest in the global health and women’s health sectors, we believe that ABI-2280 is well positioned to address several critical unmet needs in these areas, “said Gail Maderis, President and CEO of Antiva. “As a nonsurgical treatment, ABI-2280 has the potential to offer a therapeutic that maintains reproductive health of women, is self-administered at home, and improves access to care in underserved communities with scarce obstetrics / gynecology are particularly valuable in Low and middle income countries (LMIC) that account for the majority of the more than 300,000 annual cervical cancer deaths worldwide. “

“As an investor targeting companies dealing with high level public health challenges in historically overlooked market segments, we believe Antiva is a perfect fit for our investment approach. By using novel technology to develop a topical treatment for HPV-related diseases that often lead to invasive cancers. ”Antiva is working to meet a large global unmet clinical need with the goal of providing access to treatments for women around the world, “said Ms. Yip.” We are proud to support the company’s efforts in this area and look forward to further development of ABI-2280 as it hits the clinic. “

In conjunction with the completion of the Series D funding, Antiva and Adjuvant are establishing a global health committee to accelerate the global development and commercialization of ABI-2280 in low and middle income countries. The committee is chaired by Clifford Samuel, Director of Antiva and former Senior Vice President of Global Patient Solutions at Gilead, who brings over two decades of experience developing and commercializing global health therapeutics.

About HPV-related diseases and cervical cancer

The human papillomavirus (HPV) is so common that almost all sexually active men and women will become infected with the virus at some point in their lives. While many of these are temporary infections that the body can fight off, the persistent infections are known to drive the formation of malignancies, including cervical, anal, vulvar, penile, and head and neck cancers.

The introduction of prophylactic vaccines against HPV was an important step in the fight against HPV-associated cancers by preventing infection with certain high-risk HPV subtypes. Due to the low acceptance rates in the US, EU and Japan, and limited access to vaccines in developing countries, HPV infections, and the disease states caused by such infections remain a great unmet clinical need.

Cervical cancer is the fourth most common cancer in women worldwide and, as such, poses a major public health problem. An estimated 570,000 women worldwide were diagnosed with cervical cancer and approximately 311,000 women died of the disease in 2018, according to the World Health Organization.

About Antiva Biosciences
Antiva Biosciences, Inc. is a clinical-stage biopharmaceutical company developing novel topical therapeutics for the treatment of diseases caused by HPV infection. The company based in South San Francisco, was founded in 2012 by Dr. Karl Hostetler from The. founded University of California San Diego. The company’s lead drug candidate, ABI-2280, is initially being developed as a topical treatment for high-grade cervical intraepithelial neoplasia (HSIL, CIN 2,3). Antiva believes that the development of ABI-2280 can be extended to other HPV-related precancerous lesions, such as: B. vulvar (VIN 2,3) and anal (AIN 2,3) neoplasms.

Further information is available at: www.antivabio.com.

Contact information:
Gail Maderis
Antiva Biosciences, Inc.
650-822-1401
[email protected]

Tim Brons
Strategic partner of Vida (media)
646-319-8981
[email protected]

SOURCE Antiva Biosciences, Inc.

Share.

Comments are closed.